Clinical Trials Logo

Clinical Trial Summary

The overall aim of this clinical pilot study is to develop an optimal design (e.g. dose, study duration) for the main clinical study. In the main study factors that influence dOFM data variability will be measured to develop a general BE testing method using dOFM for dermatological drug products.


Clinical Trial Description

In this herein described pilot study 6 subjects will receive three different topical doses of Lidocaine 2.5% and Prilocaine 2.5% cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US ) to select an optimal dose for the main study. Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US) will be applied to assess whether it can be used as negative control in the main study. Blood samples will also be drawn at prior to dosing to establish a baseline, and at defined time points post-dose to assess systemic drug levels. Furthermore, lateral diffusion from a dosed site to an adjacent (non-dosed) test site will be evaluated in this pilot study. Different non-invasive devices will be tested to identify influencing factors for skin penetration in order to complete the available information on skin characteristics for the main study.

This pilot will be a single center, open label, exploratory research study to assess the dermal PK of marketed topical formulations of lidocaine/prilocaine in six healthy volunteers using dOFM. The study will be performed at the Clinical Research Center of the Medical University of Graz/Austria.The study comprises three visits, a screening visit (Visit 1), a study visit of approximately 28 h (Visit 2) for application of dermatological drug products, and an End-of-Study visit (Visit 3). In Visit 2 each subject will have nine test sites, four on the left thigh, four on the right thigh (resulting in 8 test sites on both thighs) and one on the arm. Each of the nine test site will have 2 dOFM probes resulting in 18 dOFM probes per subject. On six of the eight test sites on the thighs three different doses of Lidocaine 2.5% and Prilocaine 2.5% cream cream will be applied (5 mg/cm², 10 mg/cm² or 15 mg/cm²) to assess the dose for the main study. On another test site on the thighs Oraqix® gel will be applied to check if Oraqix® can be used as negative control in the main study. On the remaining test site on the thighs as well as on the test site on the arm no products will be applied to test for potential cross-talk between test sites by lateral diffusion and systemic redistribution, resulting in seven treated and two non-treated sites per subject. Additionally 8 blood samples will be drawn to rule out systemic appearance of lidocaine and/or prilocaine. Further, devices to identify possible factors influencing skin penetration will be measured on each thigh (e.g. TEWL). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03613207
Study type Interventional
Source Joanneum Research Forschungsgesellschaft mbH
Contact
Status Completed
Phase N/A
Start date March 22, 2018
Completion date May 3, 2018

See also
  Status Clinical Trial Phase
Completed NCT03270241 - Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy N/A
Completed NCT03246945 - Photograph Quality Rating Scale Study ("PQRS Study") N/A
Completed NCT03467685 - Variable Perception of Cutaneous Stimulation N/A
Completed NCT03344497 - Animated Video Consultation for Reducing Pre-Operative Anxiety in Outpatient Dermatologic Surgery N/A
Terminated NCT03497455 - Utility of Digital Dermoscopy in the Skin Cancer Clinic
Recruiting NCT03893643 - Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
Completed NCT03651167 - Skin Tone Preferences and Their Influence on Skin Care Behaviors
Completed NCT03489356 - Project Options - The ABC Method N/A
Recruiting NCT03132142 - Desensitization of Nociceptive Afferents by Application of Topical Capsaicin, Trans-cinnamaldehyde and L-menthol N/A
Completed NCT03944278 - Pilot Evaluation of Thulium Laser Alone or in Combination With Broad Band Light for Treatment of Dermatologic Conditions N/A